{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-106362","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2024-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.076556+00:00","generated_at":"2026-05-31T04:56:54.659385+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Prelude reports Phase 1 interim data: PRT3789 shows 3 confirmed PRs in NSCLC/esophageal, well tolerated","bullets":["3 confirmed partial responses in 2 esophageal and 1 NSCLC patient out of 26 evaluable; 7 patients had tumor shrinkage.","PRT3789 was well tolerated in 65 patients; no dose-limiting toxicities or drug-related serious adverse events.","Dose escalation continues to cohort 9 (500 mg once weekly); MTD not yet reached.","Company expects to confirm biologically active dose as monotherapy by year-end.","Data presented at ESMO 2024; also selected for plenary session at EORTC-NCI-AACR Symposium in October 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-106362","json":"https://secwatch.observer/filing/0000950170-24-106362.json","markdown":"https://secwatch.observer/filing/0000950170-24-106362.md","text":"https://secwatch.observer/filing/0000950170-24-106362.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000095017024106362/0000950170-24-106362-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000095017024106362/prld-20240913.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:56:54.659385+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}